{"id":55557,"date":"2026-09-28T06:21:57","date_gmt":"2026-09-28T06:21:57","guid":{"rendered":"https:\/\/www.theisn.org\/?p=55557"},"modified":"2026-09-28T06:43:31","modified_gmt":"2026-09-28T06:43:31","slug":"isn-journal-summaries-on-pegcetacoplan-avf-maturation-failure-and-primary-hyperoxaluria-type-1","status":"publish","type":"post","link":"https:\/\/www.theisn.org\/blog\/2026\/09\/28\/isn-journal-summaries-on-pegcetacoplan-avf-maturation-failure-and-primary-hyperoxaluria-type-1\/","title":{"rendered":"ISN Journal summaries on pegcetacoplan, AVF maturation failure, and primary hyperoxaluria type 1\u00a0"},"content":{"rendered":"<p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3><i><span data-contrast=\"none\">Kidney International<\/span><\/i><span data-contrast=\"none\">\u00ae\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/h3>\n<p><a href=\"https:\/\/www.kidney-international.org\/article\/S0085-2538(26)00433-3\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-55560\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/09\/KI-VA-1-300x169.jpg\" alt=\"\" width=\"360\" height=\"203\" \/><\/span><\/b><\/a><\/p>\n<p><a href=\"https:\/\/www.kidney-international.org\/article\/S0085-2538(26)00433-3\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">Real-world outcomes of pegcetacoplan in primary membranoproliferative glomerulonephritis<\/span><\/b><\/a><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pegcetacoplan is being explored as a treatment for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, but real-world evidence remains limited. <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This observational study followed 25 pediatric and adult patients treated outside clinical trials, most of whom had not responded to conventional therapies.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Pegcetacoplan was associated with rapid and sustained reductions in proteinuria, stable or improved kidney function, normalization of serum C3, and good tolerability, supporting its potential as an effective option for complement-mediated kidney disease.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<h3><i><span data-contrast=\"none\">Kidney International Reports\u00ae<\/span><\/i><i><span data-contrast=\"auto\">\u202f<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/h3>\n<p><a href=\"https:\/\/www.kireports.org\/article\/S2468-0249(26)02919-0\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-55559\" src=\"https:\/\/www.theisn.org\/wp-content\/uploads\/2026\/09\/KIR-VA-300x173.jpg\" alt=\"\" width=\"347\" height=\"200\" \/><\/span><\/b><\/a><\/p>\n<p><a href=\"https:\/\/www.kireports.org\/article\/S2468-0249(26)02919-0\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">Preoperative serum alkaline phosphatase predicts arteriovenous fistula maturation failure<\/span><\/b> <\/a><span data-contrast=\"none\">\u202f\u202f<\/span><\/p>\n<p><span data-contrast=\"auto\">Arteriovenous fistula (AVF) maturation failure is a major challenge in hemodialysis, but reliable preoperative predictors are limited.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This study combined multiomics analysis with validation in 55 patients to identify molecular markers linked to AVF maturation failure.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Higher tissue-nonspecific alkaline phosphatase and preoperative serum alkaline phosphatase were associated with maturation failure, suggesting serum alkaline phosphatase could serve as a practical biomarker to help identify patients at higher risk before AVF creation.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<h3><i><span data-contrast=\"none\">Kidney International Case Reports\u2122<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/h3>\n<p><a href=\"https:\/\/www.kicasereports.org\/article\/S3117-471X(26)00032-4\/fulltext\" target=\"_blank\" rel=\"noopener\"><b><span data-contrast=\"none\">Rescue of renal function after novel RNA interference therapy (lumasiran) for catastrophic post\u2013kidney transplant recurrent oxalate nephropathy in primary hyperoxaluria type 1<\/span><\/b><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Primary hyperoxaluria type 1 can be difficult to diagnose, and delayed recognition may lead to recurrent oxalate deposition and graft dysfunction after kidney transplantation.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">This case report describes a 23-year-old woman diagnosed only after transplantation, when worsening graft function prompted genetic testing. Lumasiran reduced oxalate levels and stabilized transplant function for 18 months.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">The case highlights the importance of considering genetic or metabolic causes of unexplained kidney failure. It suggests lumasiran may have a role as salvage therapy in selected adults diagnosed after transplantation.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] Kidney International\u00ae\u202f\u00a0 Real-world outcomes of pegcetacoplan in primary membranoproliferative glomerulonephritis\u00a0 Pegcetacoplan is being explored as a treatment for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, but real-world evidence remains limited. \u00a0 This observational study followed 25 pediatric and adult patients treated outside clinical trials, most of whom had not responded to conventional therapies.\u00a0\u00a0 Pegcetacoplan [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":29446,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[98,36],"tags":[586,585,587],"class_list":["post-55557","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-journals","category-news","tag-arteriovenous-fistula-maturation-failure","tag-membranoproliferative-glomerulonephritis","tag-primary-hyperoxaluria-type-1"],"featured_image_src":{"landsacpe":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-1024x445.jpg",1024,445,true],"list":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-366x246.jpg",366,246,true],"medium":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-300x200.jpg",300,200,true],"full":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3.jpg",1024,681,false]},"_links":{"self":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55557"}],"collection":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/comments?post=55557"}],"version-history":[{"count":3,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55557\/revisions"}],"predecessor-version":[{"id":55562,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/55557\/revisions\/55562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media\/29446"}],"wp:attachment":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media?parent=55557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/categories?post=55557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/tags?post=55557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}